

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Cardiovascular and Renal Drugs Advisory Committee (CRDAC) Meeting
December 8, 2021

DRAFT QUESTIONS

The Applicant is seeking approval of bardoxolone methyl to slow the progression of chronic kidney disease caused by Alport syndrome in patients 12 years of age and older.

1. **DISCUSSION:** Discuss whether CARDINAL Phase 3 was adequately designed to assess for an effect on the progression of chronic kidney disease in patients with Alport syndrome.
2. **DISCUSSION:** Discuss whether the available data indicate that bardoxolone methyl slows the progression of chronic kidney disease and whether it is reasonable to conclude, based on the available data, that bardoxolone methyl will reduce the risk of progression to kidney failure when used chronically in patients with Alport syndrome.
3. **DISCUSSION:** Discuss bardoxolone methyl's safety profile.
 - a. Do bardoxolone methyl's effects on albuminuria and blood pressure raise concerns about its long-term efficacy and safety in patients with Alport syndrome?
 - b. What are the implications of bardoxolone methyl's effect on body weight for pediatric patients?
4. **VOTE:** Does the provided evidence demonstrate that bardoxolone methyl is effective in slowing the progression of chronic kidney disease in Alport syndrome and that its benefits outweigh its risks?
 - a. If you voted yes, provide your rationale.
 - b. If you voted no, provide your rationale and provide recommendations for additional data and/or analyses that are needed to support approval.